Opinion
Video
A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.
China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma